CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab

Cancer Investigation

Volumn 30, Issue 1, 2012, Pages 65-71

  Petrioli, Roberto ^a   Licchetta, Antonella ^a   Roviello, Giandomenico ^a   Pascucci, Alessandra ^a   Francini, Edoardo ^a   Bargagli, Gianluca ^a   Conca, Raffaele ^a   Miano, Salvatora Tindara ^a   Marzocca, Giuseppe ^a   Francini, Guido ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Bevacizumab; CA19.9; Capecitabine; CEA; Colorectal cancer; Oxaliplatin; Tumor markers

Indexed keywords

BEVACIZUMAB; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; COLORECTAL CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROGNOSIS;

EID: 84855827235     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.629380     Document Type: Article

References (25)

1. Pañares RL, Garcia AA. Bevacizumab in the management of solid tumors. Expert Rev Anticancer Ther 2007;7:433-445. (Pubitemid 46681799)
2. Scheithauer W, Kornek GV, Raderer M, Schüll B, Schmid K, KovatsE, Schneeweiss B, LangF, LenauerA,DepischD. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003;21:1307-1312. (Pubitemid 46606408)
3. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, Debraud F, FigerA,Grossmann J, Sawada N, Schoïffski P, Sobrero A, Van Cutsem E, Díaz-Rubio E. XELOX (capecitabine plus xaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;12:2084-2091. (Pubitemid 41095141)
4. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008:26:2013-2019.
5. Cao Y, Tan A, Gao F, Liu L, Liao C, Mo Z. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone inmetastatic colorectal cancer. Int J Colorectal Dis 2009;24:677-685.
6. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006;42:1031-1039.
7. Mayer RJ, Garnick MB, Steele, GD Jr, Zamcheck N. Carcinoembryonic antigen (CEA) as a monitor of chemotherapy in disseminated colorectal cancer. Cancer 1978;42(Suppl. 3):1428-1433. (Pubitemid 9038269)
8. Filella X, Molina R, Grau JJ, Piqué JM, Garcia-Valdecasas JC, Astudillo E, Biete A, Bordas JM, Novell A, Campo E. Prognostic value of CA 19.9 levels in colorectal cancer. Ann Surg 1992;216:55-59.
9. Iwanicki-Caron I, Di Fiore F, Roque I, Astruc E, Stetiu M, Duclos A, Tougeron D, Saillard S, Thureau S, Benichou J, Paillot B, Basuyau JP, Michel P. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol 2008;26:3681-3686.
10. Chapman MA, Buckley D, Henson DB, Armitage NC. Preoperative carcinoembryonic antigen is related to tumour stage and longtermsurvival in colorectal cancer. Br J Cancer 1998;78:1346-1349. (Pubitemid 28495248)
11. Gogas H, Lofts FJ, Evans TR, Daryanani S, Mansi JL. Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? Br J Cancer 1998;77:325-328. (Pubitemid 28029551)
12. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-del Castillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;24:2897-2902. (Pubitemid 46630592)
13. Ward U, Primrose JN, Finan PJ, Perren TJ, Selby P, Purves DA, Cooper EH. The use of tumour markers CEA, CA-195 and CA- 242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer. Br J Cancer 1993;67:1132-1135. (Pubitemid 23147517)
14. GremJL, Steinberg SM, Chen AP, et al. The utility ofmonitoring carcinoembyronic antigen during systemic therapy for advanced colorectal cancer. Oncol Rep 1998;5:559-567. (Pubitemid 28189305)
15. Hanke B, Riedel C, Lampert S, Happich K, Martus P, Parsch H, Himmler B, Hohenberger W, Hahn EG, Wein A. CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA). Ann Oncol 2001;12:221-226. (Pubitemid 32223872)
16. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988;240:1285-1293.
17. Petrioli R, Paolelli L, Marsili S, Civitelli S, Francini E, Cioppa T, Roviello F, Nettuno R, Intrivici C, Tanzini G, Lorenzi M, Francini G. FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. Oncology 2006;70:345-350. (Pubitemid 46074943)
18. Petrioli R, Bargagli G, Lazzi S, Pascucci A, Francini E, Bellan C, Conca R, Martellucci I, Fiaschi AI, Lorenzi B, Francini G, Multidisciplinary Oncology Group in Gastrointestinal Tumors. (2008). Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin. Anticancer Drugs 2010;21:313-319.
19. Ailawadhi S, Sunga A, Rajput A, Yang GY, Smith J, Fakih M. Chemotherapy-induces carcinomebryonic antigen surge in patients with metastatic colorectal cancer. Oncology 2006;70:49-53.
20. Kim HJ, Lee KW, Kim YJ, Oh DY, Kim JH, IM SA, Lee JS. Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer. Acta Oncol 2009;48:385-390.
21. LockerGY, Hamilton S, Harris J, Jessup JM,KemenyN,Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr; ASCO. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-5327. (Pubitemid 46631379)
22. de Haas RJ, Wicherts DA, Flores E, Ducreux M, Lévi F, Paule B, Azoulay D, Castaing D, Lemoine A, Adam R. Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases. Ann Surg Oncol 2010;17:1010-1023.
23. Formica V, Massara MC, Portarena I, Fiaschetti V, Grenga I, Del Vecchio Blanco G, Sileri P, Tosetto L, Skoulidis F, Pallone F, Roselli M. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients. Cancer Biomark 2009;5:167-175.
24. Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, Rivkin SE, Macdonald JS, Geyer CE Jr, Sandbach J, Wolf DL, Mohrland JS, Elfring GL, Miller LL, Von Hoff DD. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999;85:786-795. (Pubitemid 29077554)
25. Tsai HL, Chang YT, Chu KS, Chen CF, Yeh YS,Ma CJ, Wu DC, Kuo CH, ChanHM, SheenMC,Wang JY. Carcinoembryonic antigen in monitoring of response to cetuximab plus FOLFIRI or FOLFOX-4 in patients with metastatic colorectal cancer. Int J Biol Markers 2008;23:244-248.